| Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (NCT05332925) | Jun Zhang, MD, PhD | 2022-07-21 |
| Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) (NCT05465343) | Peking Union Medical College | 2022-07-11 |
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 (NCT05383482) | Laekna Limited | 2022-07-01 |
| Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer (NCT05387109) | Tang-Du Hospital | 2022-06-30 |
| Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation (NCT06247280) | Yuhan Corporation | 2022-06-24 |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (NCT05429320) | Memorial Sloan Kettering Cancer Center | 2022-06-15 |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers (NCT04712877) | Lung Cancer Mutation Consortium | 2022-06-15 |
| Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) (NCT05382728) | TYK Medicines, Inc | 2022-06-08 |
| A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor (NCT05332574) | Genor Biopharma Co., Ltd. | 2022-05-17 |
| A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (NCT05378763) | Spectrum Pharmaceuticals, Inc | 2022-05-12 |
| Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (NCT05146219) | TYK Medicines, Inc | 2022-04-02 |
| ERK Inhibitor JSI-1187 in Advanced Solid Tumors (NCT06239623) | JS InnoPharm, LLC | 2022-04-02 |
| Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations (NCT05277701) | Yonsei University | 2022-04-01 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations (NCT05256290) | Black Diamond Therapeutics, Inc. | 2022-03-31 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium (NCT05273827) | Tianjin Medical University Cancer Institute and Hospital | 2022-03-22 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT05621837) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2022-03-10 |
| Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment (NCT06095934) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2022-03-01 |
| RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC (NCT05273047) | Intergroupe Francophone de Cancerologie Thoracique | 2022-03-01 |
| Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC (NCT05209256) | The First Affiliated Hospital of Henan University of Science and Technology | 2022-03-01 |
| The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases? (NCT05378633) | University Hospital Heidelberg | 2022-02-24 |
| Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (NCT05117658) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-02-18 |
| Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis (NCT05165160) | University Hospital, Montpellier | 2022-02-15 |
| Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (NCT04772235) | Instituto Oncológico Dr Rosell | 2022-02-11 |
| Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (NCT05089916) | AIO-Studien-gGmbH | 2022-01-20 |
| PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study (NCT05222087) | Peter MacCallum Cancer Centre, Australia | 2022-01-03 |
| Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma (NCT05132985) | Liaoning Cancer Hospital & Institute | 2022-01-01 |
| Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma (NCT05165355) | Tongji University | 2021-12-28 |
| Lorlatinib Continuation Study (NCT05144997) | Pfizer | 2021-12-28 |
| Crizotinib Continuation Clinical Study (NCT05160922) | Pfizer | 2021-12-27 |
| Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (NCT04939701) | Astellas Pharma Global Development, Inc. | 2021-12-23 |
| Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. (NCT05615142) | Sichuan University | 2021-12-15 |
| Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) (NCT05061017) | Diwakar Davar | 2021-12-09 |
| QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration (NCT06766565) | Fuzhou General Hospital | 2021-12-08 |
| Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC (NCT05207371) | GAIA BioMedicine Inc. | 2021-12-01 |
| Tislelizumab in Addition to BACE in Patients with NSCLC (NCT05058560) | The First Affiliated Hospital of Zhengzhou University | 2021-12-01 |
| First in Human Study of TORL-1-23 in Participants With Advanced Cancer (NCT05103683) | TORL Biotherapeutics, LLC | 2021-11-17 |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation (NCT05065398) | Shanghai Henlius Biotech | 2021-11-15 |
| Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (NCT05007769) | Washington University School of Medicine | 2021-10-31 |
| A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05117476) | Cullinan Therapeutics Inc. | 2021-10-29 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients (NCT05078931) | Shanghai Chest Hospital | 2021-10-27 |
| Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC (NCT04989322) | Dr Joanne CHIU | 2021-10-05 |
| Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC (NCT05021328) | Hubei Cancer Hospital | 2021-10-01 |
| Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation (NCT04958967) | Allist Pharmaceuticals, Inc. | 2021-10-01 |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (NCT05059522) | Pfizer | 2021-09-29 |
| A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. (NCT05005468) | Shanghai Chest Hospital | 2021-09-01 |
| AI-EBUS-Elastography for LN Staging (NCT04816981) | St. Joseph's Healthcare Hamilton | 2021-09-01 |
| Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer (NCT04822298) | Amgen | 2021-08-31 |
| Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC (NCT04585490) | Maximilian Diehn | 2021-08-25 |
| Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors (NCT04780217) | ImmVira Pharma Co. Ltd | 2021-08-10 |
| JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety (NCT04874844) | Beijing Dongfang Biotech Co., Ltd. | 2021-07-30 |
| A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC (NCT04849273) | Turning Point Therapeutics, Inc. | 2021-07-28 |
| A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China (NCT05009329) | Allist Pharmaceuticals, Inc. | 2021-07-26 |
| Uniportal Tubeless VATS for the Evaluation of Biopsy for Second-generation Sequencing in Patients With Advanced NSCLC (NCT04950907) | Jianxing He | 2021-07-15 |
| Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis (NCT04944069) | Second Affiliated Hospital of Nanchang University | 2021-07-01 |
| To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations (NCT04969965) | EQRx, Inc. | 2021-06-21 |
| An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network (NCT04564079) | Exactis Innovation | 2021-06-01 |
| 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC (NCT04996927) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-06-01 |
| Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (NCT04870190) | Shanghai Chest Hospital | 2021-06-01 |
| CPAP or BiPAP for Motion Mitigation During Radiotherapy (NCT04986293) | University Medical Center Groningen | 2021-06-01 |
| A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation (NCT03955198) | Institut Claudius Regaud | 2021-05-27 |
| Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. (NCT04720339) | University Hospital, Strasbourg, France | 2021-05-27 |
| Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient (NCT07198217) | Zibo Municipal Hospital | 2021-05-25 |
| A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (NCT04746924) | BeiGene | 2021-05-24 |
| Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB) (NCT06823401) | Fondazione Ricerca Traslazionale | 2021-05-20 |
| An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib (NCT04764188) | Hoffmann-La Roche | 2021-05-10 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors (NCT04686682) | Jacobio Pharmaceuticals Co., Ltd. | 2021-05-07 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) (NCT04863248) | G1 Therapeutics, Inc. | 2021-04-30 |
| Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (NCT04892849) | University of Erlangen-Nürnberg Medical School | 2021-04-30 |
| A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients (NCT03866499) | Beta Pharma Shanghai | 2021-04-30 |
| Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment (NCT04820023) | Bridge Biotherapeutics, Inc. | 2021-04-02 |
| High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization (NCT04826913) | University Hospital, Strasbourg, France | 2021-04-01 |
| Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors (NCT04665206) | Vivace Therapeutics, Inc | 2021-03-24 |
| JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors (NCT04720976) | Allist Pharmaceuticals, Inc. | 2021-03-23 |
| A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) (NCT04778800) | Henan Cancer Hospital | 2021-03-20 |
| A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor (NCT04691388) | Zhejiang Cancer Hospital | 2021-03-01 |
| Epidemiology of Young Lung Cancer - Survey (NCT04640259) | Addario Lung Cancer Medical Institute | 2021-02-01 |
| A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (NCT04736823) | Akeso | 2021-02-01 |
| Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy (NCT04716946) | Memorial Sloan Kettering Cancer Center | 2021-01-27 |
| A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors (NCT04672460) | Pfizer | 2020-12-21 |
| Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients (NCT04552613) | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 2020-11-23 |
| Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC (NCT04909684) | Radboud University Medical Center | 2020-11-18 |
| A Trial of AK104 Plus Anlotinib in NSCLC (NCT04646330) | Akeso | 2020-11-18 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC (NCT06001671) | Hunan Province Tumor Hospital | 2020-10-27 |
| Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (NCT04549025) | Jounce Therapeutics, Inc. | 2020-10-19 |
| Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (NCT04476797) | Galera Therapeutics, Inc. | 2020-10-18 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (NCT04575415) | Guangdong Association of Clinical Trials | 2020-10-07 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| Study to Evaluate D-1553 in Subjects With Solid Tumors (NCT04585035) | InventisBio Co., Ltd | 2020-10-02 |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT04370587) | ImmVira Pharma Co. Ltd | 2020-09-17 |
| Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer (NCT04506242) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-09-15 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC (NCT03801200) | Hubei Cancer Hospital | 2020-09-10 |
| Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients (NCT04557007) | Oslo University Hospital | 2020-09-01 |
| Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (NCT04858958) | Allist Pharmaceuticals, Inc. | 2020-08-10 |
| Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors (NCT04556669) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-08-01 |
| Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) (NCT04245514) | Swiss Cancer Institute | 2020-07-15 |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer (NCT03628144) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-01 |